Takeda Pharmaceutical Co Ltd (NYSE:TAK) Holdings Increased by Velanne Asset Management Ltd

Velanne Asset Management Ltd lifted its stake in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 5,270.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 281,972 shares of the company’s stock after acquiring an additional 276,722 shares during the period. Takeda Pharmaceutical accounts for approximately 4.0% of Velanne Asset Management Ltd’s portfolio, making the stock its 16th biggest position. Velanne Asset Management Ltd’s holdings in Takeda Pharmaceutical were worth $5,744,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Contravisory Investment Management Inc. purchased a new position in shares of Takeda Pharmaceutical during the 1st quarter worth $28,000. Shine Investment Advisory Services Inc. purchased a new position in shares of Takeda Pharmaceutical during the 1st quarter worth $28,000. First Hawaiian Bank purchased a new position in shares of Takeda Pharmaceutical during the 1st quarter worth $35,000. Dubuque Bank & Trust Co. purchased a new position in shares of Takeda Pharmaceutical during the 1st quarter worth $41,000. Finally, Edge Wealth Management LLC purchased a new position in shares of Takeda Pharmaceutical during the 1st quarter worth $55,000. Institutional investors and hedge funds own 3.63% of the company’s stock.

TAK has been the topic of several research analyst reports. Zacks Investment Research upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating and set a $23.00 price objective on the stock in a report on Wednesday, March 13th. Goldman Sachs Group restated a “buy” rating on shares of Takeda Pharmaceutical in a report on Tuesday, March 19th.

TAK traded up $0.43 on Thursday, hitting $19.05. The company had a trading volume of 2,294,383 shares, compared to its average volume of 3,653,999. The firm has a market cap of $28.67 billion, a P/E ratio of 17.80 and a beta of 0.66. Takeda Pharmaceutical Co Ltd has a 1 year low of $15.50 and a 1 year high of $21.99. The company has a current ratio of 3.06, a quick ratio of 2.81 and a debt-to-equity ratio of 1.19.

ILLEGAL ACTIVITY NOTICE: This report was first published by Baseball Daily News and is the property of of Baseball Daily News. If you are viewing this report on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/velanne-asset-management-ltd-boosts-stake-in-takeda-pharmaceutical-co-ltd-tak.html.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Read More: What is the Dividend Aristocrat Index?

Institutional Ownership by Quarter for Takeda Pharmaceutical (NYSE:TAK)

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.